Close Menu

NEW YORK – Medical technology firm Bioloidics said today that it is teaming up with the Agency for Science, Technology and Research's (A*STAR) Genome Institute of Singapore to develop a circulating tumor cell assay that can assess minimal residual disease and predict relapse in women with surgically-treated breast cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.